Failed Drug Trial Impacts AstraZeneca's Market Value

AstraZeneca's market value dropped by nearly 26 billion euros after a new heart medication proved ineffective in trials, though the British pharmaceutical giant maintains strong growth.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

fazGerman30d ago

Britischer Pharmakonzern: Gescheiterter Medikamententest belastet Astra-Zeneca

Fast 26 Milliarden Euro Börsenwert gehen verloren, nachdem ein Test ergeben hat, dass ein neues Herzmedikament praktisch wirkungslos ist. Doch trotz des Rückschlags bleibt Astra-Zeneca auf starkem Wachstumskurs.

Read full article →

PERSPECTA

PERSPECTA

Failed Drug Trial Impacts AstraZeneca's Market Value

Sources

Britischer Pharmakonzern: Gescheiterter Medikamententest belastet Astra-Zeneca

Related Stories

Stock Market Flashes Dot-Com Bubble Warning Signal

Qorvo's $22 Billion Merger Impacts Insider Filings

AMD Challenges Nvidia with Bold New Move

Multiple Companies Release Q2 Earnings Call Highlights

PERSPECTA